37 patents
Utility
Method and Compositions for Inhibiting or Preventing Adverse Effects of Oral Antibiotics
21 Dec 23
This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Michael KALEKO, Sheila CONNELLY, Vincent John WACHER
Filed: 2 Feb 23
Utility
Methods and Compositions for Attenuating Antibiotic Resistance
14 Dec 23
The present invention provides, in part, therapeutic beta-lactamases that can, inter alia, mitigate antibiotic resistance.
Sheila CONNELLY, Michael KALEKO
Filed: 25 May 23
Utility
Modified Beta-lactamases and Methods and Uses Related Thereto
19 Oct 23
Pertti KOSKI, Ulla AIRAKSINEN, Katja VALIMAKI
Filed: 10 May 23
Utility
Alkaline Phosphatase Agents for Treatment of Radiation Disorders
5 Oct 23
The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
Filed: 14 Apr 23
Utility
Beta-lactamases with Improved Properties for Therapy
5 Oct 23
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Michael KALEKO, Sheila CONNELLY
Filed: 7 Feb 23
Utility
Intestinal Alkaline Phosphatase Formulations
7 Sep 23
The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
Filed: 17 Mar 23
Utility
E. Coli-based Production of Beta-lactamase
7 Sep 23
The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells.
Andrew BRISTOL, Michael KALEKO, Steven HUBERT
Filed: 1 Dec 22
Utility
Microbiome Protection from Oral Antibiotics
31 Aug 23
This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
Michael KALEKO, Sheila CONNELLY
Filed: 26 Oct 22
Utility
Alkaline Phosphatase Formulations and Uses Thereof
13 Oct 22
The present invention provides, in part, formulations comprising an alkaline phosphatase.
Michael KALEKO, Ray STAPLETON, Andrew BRISTOL, Steven HUBERT, Cristina FREIRE
Filed: 3 Jun 20
Utility
Intestinal Alkaline Phosphatase-based Treatments of Metabolic Disorders
18 Aug 22
The present invention relates, inter alia, to combination therapies of specific commensal gastrointestinal bacteria with therapeutic intestinal alkaline phosphatases for the treatment of disease, such as metabolic disorders.
Christian FURLAN FREGUIA
Filed: 16 Jul 20
Utility
Alkaline Phosphatase Agents for Treatment of Neurodevelopmental Disorders
4 Aug 22
The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
Filed: 21 Apr 22
Utility
Beta-lactamase Compositions for Treatment of Graft Versus Host Disease
14 Jul 22
The present invention relates to, in part, methods and compositions for reducing the incidence and/or severity of complications associated with IV beta-lactam antibiotic use in allo-HCT recipients, such as aGVHD and VRE colonization and/or VRE bloodstream infection, using beta-lactamase agents.
Michael KALEKO, Sheila CONNELLY, Marcel R.M. VAN DEN BRINK, Jonathan PELED, Marina Burgos DA SILVA
Filed: 5 May 20
Utility
Alkaline Phosphate-based Oncology Treatments
30 Jun 22
The present invention relates to methods and compositions for preventing, treating, or reducing chemotherapy treatment-mediated side effects, including gastrointestinal (GI) side effects, comprising administering to a subject intestinal alkaline phosphatases (IAP).
Christian FURLAN FREGUIA, Michael KALEKO
Filed: 5 May 20
Utility
Safe and Effective Beta-lactamase Dosing for Microbiome Protection
28 Apr 22
The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.
Joseph Sliman
Filed: 10 Jan 22
Utility
Beta-lactamases with Improved Properties for Therapy
31 Mar 22
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Michael KALEKO, Sheila CONNELLY
Filed: 8 Dec 21
Utility
Modified Beta-lactamases and Methods and Uses Related Thereto
24 Mar 22
Pertti KOSKI, Ulla AIRAKSINEN, Katja VALIMAKI
Filed: 23 Nov 21
Utility
Carbapenemases for Use with Antibiotics for the Protection of the Intestinal Microbiome
6 Jan 22
This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
Michael KALEKO, Sheila CONNELLY
Filed: 19 Aug 21
Utility
E. Coli-based Production of Beta-lactamase
28 Oct 21
The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells.
Andrew BRISTOL, Michael KALEKO, Steven HUBERT
Filed: 7 May 21
Utility
Stabilized Pertussis Antibodies with Extended Half-life
28 Oct 21
The present invention relates, in part, to modified humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents.
Jennifer MAYNARD, Annalee NGUYEN, Michael KALEKO
Filed: 15 Aug 17
Utility
Alkaline Phosphatase Formulations
22 Jul 21
The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent.
Vincent WACHER, J. Blair WEST, Michael KALEKO, Christian FURLAN FREGUIA
Filed: 29 Mar 21